Literature DB >> 32306409

Combinatorial Tim-3 and PD-1 activity sustains antigen-specific Th1 cell numbers during blood-stage malaria.

Rebecca S Dookie1, Ana Villegas-Mendez1, Hans Kroeze2, Jordan R Barrett3, Simon J Draper3, Blandine M Franke-Fayard2, Chris J Janse2, Andrew S MacDonald1, Kevin N Couper1.   

Abstract

AIMS: Co-inhibitory receptors play a major role in controlling the Th1 response during blood-stage malaria. Whilst PD-1 is viewed as the dominant co-inhibitory receptor restricting T cell responses, the roles of other such receptors in coordinating Th1 cell activity during malaria are poorly understood. METHODS AND
RESULTS: Here, we show that the co-inhibitory receptor Tim-3 is expressed on splenic antigen-specific T-bet+ (Th1) OT-II cells transiently during the early stage of infection with transgenic Plasmodium yoelii NL parasites expressing ovalbumin (P yoelii NL-OVA). We reveal that co-blockade of Tim-3 and PD-L1 during the acute phase of P yoelii NL infection did not improve the Th1 cell response but instead led to a specific reduction in the numbers of splenic Th1 OT-II cells. Combined blockade of Tim-3 and PD-L1 did elevate anti-parasite IgG antibody responses. Nevertheless, co-blockade of Tim-3 and PD-L1 did not affect IFN-γ production by OT-II cells and did not influence parasite control during P yoelii NL-OVA infection.
CONCLUSION: Thus, our results show that Tim-3 plays an unexpected combinatorial role with PD-1 in promoting and/ or sustaining a Th1 cell response during the early phase of blood-stage P. yoelii NL infection but combined blockade does not dramatically influence anti-parasite immunity.
© 2020 The Authors. Parasite Immunology published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CD4+ T cells; T cell exhaustion; co-inhibitory receptors; immunoregulation; malaria

Mesh:

Substances:

Year:  2020        PMID: 32306409     DOI: 10.1111/pim.12723

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  7 in total

1.  Deciphering the Plasmodium falciparum malaria-specific CD4+ T-cell response: ex vivo detection of high frequencies of PD-1+TIGIT+ EXP1-specific CD4+ T cells using a novel HLA-DR11-restricted MHC class II tetramer.

Authors:  Sophia Schulte; Janna Heide; Christin Ackermann; Sven Peine; Michael Ramharter; Maria Sophia Mackroth; Robin Woost; Thomas Jacobs; Julian Schulze Zur Wiesch
Journal:  Clin Exp Immunol       Date:  2022-04-04       Impact factor: 4.330

Review 2.  Inhibitory immune checkpoint molecules and exhaustion of T cells in COVID-19.

Authors:  M Barnova; A Bobcakova; V Urdova; R Kosturiak; L Kapustova; D Dobrota; M Jesenak
Journal:  Physiol Res       Date:  2021-12-16       Impact factor: 1.881

3.  Exhausted PD-1+ TOX+ CD8+ T Cells Arise Only in Long-Term Experimental Trypanosoma cruzi Infection.

Authors:  Rosa Isela Gálvez; Thomas Jacobs
Journal:  Front Immunol       Date:  2022-06-03       Impact factor: 8.786

Review 4.  COVID-19 therapy with mesenchymal stromal cells (MSC) and convalescent plasma must consider exosome involvement: Do the exosomes in convalescent plasma antagonize the weak immune antibodies?

Authors:  Philip W Askenase
Journal:  J Extracell Vesicles       Date:  2020-11-14

Review 5.  Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses?

Authors:  Michael Kuske; Maximilian Haist; Thomas Jung; Stephan Grabbe; Matthias Bros
Journal:  Cancers (Basel)       Date:  2022-03-28       Impact factor: 6.639

6.  Increased Expression of Multiple Co-Inhibitory Molecules on Malaria-Induced CD8+ T Cells Are Associated With Increased Function Instead of Exhaustion.

Authors:  Johannes Brandi; Mathias Riehn; Alexandros Hadjilaou; Thomas Jacobs
Journal:  Front Immunol       Date:  2022-07-07       Impact factor: 8.786

7.  Analysis of Co-inhibitory Receptor Expression in COVID-19 Infection Compared to Acute Plasmodium falciparum Malaria: LAG-3 and TIM-3 Correlate With T Cell Activation and Course of Disease.

Authors:  Marissa Herrmann; Sophia Schulte; Nils H Wildner; Melanie Wittner; Thomas Theo Brehm; Michael Ramharter; Robin Woost; Ansgar W Lohse; Thomas Jacobs; Julian Schulze Zur Wiesch
Journal:  Front Immunol       Date:  2020-08-26       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.